Leadership

Executive Leadership
Discovery Leadership
Technology Leadership
Business Operations
Bart Henderson
CHIEF EXECUTIVE OFFICER
Bart Henderson
CHIEF EXECUTIVE OFFICER

Bart Henderson is Chief Executive Officer of Wren. Bart brings extensive experience in company-building and developing innovative medicines. Previously he was operating partner at Flagship Pioneering where he led the build-out of Harbinger Health, developing an early stage cancer detection platform with leading edge artificial intelligence and machine learning technologies. Prior to Flagship, he was CEO and co-founder of Torque (now Repertoire Immune Medicines) where, under his leadership, the company significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and building a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies. Bart was founder and president of Rhythm and its subsidiary Motus which together completed successful Phase II clinical trials for two metabolic products: setmelanotide which was granted Breakthrough Designation and is the first drug approved in the US for genetic obesity; and relamorelin which was acquired by Allergan (with Motus). He was a founding employee and chief business officer of Radius, where he built the pipeline and launched the first clinical trial for Tymlos®, now approved for the treatment of osteoporosis, and acquired Elascestrant, currently in phase 3 for the treatment of metastatic breast cancer. Previously, he was an entrepreneur-in-residence at MPM Capital. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex which launched its first product and significantly expanded its pipeline during his tenure. Bart previously held marketing management positions at Amgen and Merck. Bart received an M.B.A. from Dartmouth’s Tuck School of Business and a B.A. from Amherst College.

John Thomson, PhD
CHIEF SCIENTIFIC OFFICER
John Thomson, PhD
CHIEF SCIENTIFIC OFFICER

John Thomson is a pharmaceutical industry veteran who developed his drug-hunting skills during a 25-year career at Vertex Pharmaceuticals, a company he helped to build from the ground up. Joining the company as its third employee, he assembled and/or led progressively larger research groups and chaired or participated in numerous multidisciplinary teams tasked with evaluating new targets, projects, partnerships, and technologies. From 1993 to 1998, Dr. Thomson led the HCV research program that would eventually yield telaprevir before taking over leadership of the company’s Cambridge (USA)-based research operations. In later years, he focused on global R&D partnerships and virtual R&D networks, structuring multi-partner pacts with universities and companies with an emphasis on world health problems in economically underprivileged populations. Over the years, he was involved with all Vertex research programs spanning antivirals and anti-infectives, immunoregulation, inflammation, neurological dysfunction, cystic fibrosis, and oncology research, contributing to the discovery and selection of more than 40 development candidates—many first-in-class, and of which six were eventually approved as drugs. Dr. Thomson’s research training began in the Biochemistry Department at the University of Melbourne, Australia, where he earned a BSc (Hons.) and a PhD working on ocular lens proteins. As a Postdoctoral Associate in the Department of Physics at MIT, he explored the physics of ultra-high concentration protein phase transitions—studies that presaged current interests in condensates and protein phase separation phenomena by more than two decades. 

Pat Connelly, PhD
CHIEF OF INNOVATION
Pat Connelly, PhD
CHIEF OF INNOVATION

Pat Connelly is an entrepreneurial executive and biophysics scholar who for many years served on the Global Leadership Team responsible for management of Vertex Pharmaceuticals’ research and development enterprise. He founded, built, and led the global Materials Discovery & Characterization business unit where he and his staff co-invented three first-in-class medicines—INCIVEK® for hepatitis C, and KALYDECO® and ORKAMBI® for cystic fibrosis—and co-authored the NDAs/CTDs leading to their regulatory approvals. Dr. Connelly’s research and policy writings appear in Science, Nature, Proceedings of the National Academy of Sciences, Current Biotechnology, Biophysics Reviews, and Xconomy. Dr. Connelly also co-founded and led Vertex’s Corporate Innovation unit (VIER) and spearheaded the development of an innovation tournament called VOICE (Vertex Opportunities for Innovation & Corporation Evolution) that led to Vertex’s entry into Sickle Cell Disease (SCD). Dr. Connelly helped manage the initial implementation of the SCD project as a member of the Vertex-CRISPR Therapeutics Joint Research Committee that brought forth Exa-cel, one of the first experimental gene-editing medicines ever to be tested in humans, currently in Phase 3 clinical trials. Dr. Connelly became a founding scientist at Vertex in 1990 following postdoctoral work in Chemistry at Yale University, graduate work in Chemistry & Biochemistry at the University of Colorado, and undergraduate work at the University of Oxford and St. Michael’s College. 

Suzanne Brewerton, PhD
HEAD OF DATA & ANALYTICS
Suzanne Brewerton, PhD
HEAD OF DATA & ANALYTICS

Suzanne Brewerton is Wren’s Head of Data and Analytics. Previously, she worked at AstraZeneca where she was a senior leader in the R&D IT organisation, responsible for Data, Analytics and IT strategy for Oncology and Precision Medicine. Dr. Brewerton is a proven leader with more than 20 years’ experience working with teams in data engineering, data management, software engineering and analytics, including ML and AI, across various domains such as genomics, multi-omics and structure-based drug discovery. She has led multiple, matrixed, multi-disciplinary teams in both start-ups and pharma to build data and analytics platforms and has worked and lived in both the UK and Singapore. Dr. Brewerton completed her BSc in Biochemistry at the University of Manchester during which she became interested in computational biology and analytics. She then completed her PhD in protein structural bioinformatics at the University of Cambridge, where she studied the prediction of domain boundaries, repeating motifs and unstructured regions in proteins.

Johnny Habchi, PhD
VICE PRESIDENT, EARLY DISCOVERY
Johnny Habchi, PhD
VICE PRESIDENT, EARLY DISCOVERY

Johnny Habchi is a Founder and Vice President, Early Discovery for Wren. Previously, he worked at the Centre for Misfolding Diseases, Cambridge, where his research focused on developing new methodologies in drug discovery for protein aggregation. Dr. Habchi’s research included the first proof-of-principle studies demonstrating the mechanism of action of a small molecule drug targeting the misfolding and aggregation process, driven by a conceptual shift from structure-based to kinetics-based drug discovery in protein misfolding diseases. Dr. Habchi completed his BSc in Biochemistry at the Lebanese University during which he became interested in understanding the protein folding process. He then obtained masters and doctoral degrees in protein science from Aix-Marseille University, France, where he studied the folding of unstructured (intrinsically disordered) proteins. Dr. Habchi has co-authored more than 40 publications, is a Cambridge University Fellow in Leadership and a Fellow at Hughes Hall College, Cambridge.

Bochong Li, PhD
VICE PRESIDENT, INNOVATION
Bochong Li, PhD
VICE PRESIDENT, INNOVATION
Scott Pollack, PhD
VICE PRESIDENT, DISCOVERY ASSAY DESIGN AND INNOVATION
Scott Pollack, PhD
VICE PRESIDENT, DISCOVERY ASSAY DESIGN AND INNOVATION

Scott Pollack joined Wren Therapeutics in July 2022 as Vice President, Discovery Assay Design and Innovation. Prior to Wren, Dr. Pollack founded and led the biophysics group in the drug discovery CRO, Sygnature Discovery. He has extensive experience applying biophysics and enzymology to a broad range of drug discovery targets ranging from target validation and assay development through hit identification, characterization, and mechanistic analysis. Previous to his tenure with Sygnature, Dr. Pollack worked at Charles River and at the Merck Sharp and Dohme Neuroscience Research Centre, where he developed a strong pharmaceutical perspective applied to neurodegeneration targets and began exploring strategies for interfering with amyloidogenesis. Dr. Pollack has a BA in Chemistry from Harvard University and a PhD in Chemistry from the University of California, Berkeley, where his research focused on catalytic antibodies. He carried out postdoctoral research on mechanistic enzymology at Harvard.

Alleyn Plowright, PhD
HEAD OF DRUG DISCOVERY
Alleyn Plowright, PhD
HEAD OF DRUG DISCOVERY

Alleyn Plowright is Wren’s Head of Drug Discovery. He is a proven drug discovery leader with more than 20 years of experience across a range of therapeutic areas and has contributed to the delivery of a number of compounds to the clinic, including two compounds currently in Phase 2 clinical trials. Before joining Wren, Dr. Plowright was Head of Integrated Drug Discovery Germany for Sanofi, a multi-disciplinary research unit driving a broad drug discovery portfolio from target validation through preclinical development across a range of therapeutic modalities. Prior to Sanofi, Dr. Plowright spent 15 years with AstraZeneca in both the UK and Sweden, working with and leading cross-functional, multidisciplinary drug discovery teams as well as strategically driving scientific innovation. He is the author of more than 70 publications and patents. Dr. Plowright obtained his PhD in organic chemistry with Professor Gerald Pattenden at the University of Nottingham, UK in 1999 and continued with a two-year postdoctoral study in Chemical Biology with Professor Andrew Myers at Harvard University, U.S.

Luke Rajah, PhD
HEAD OF BUSINESS OPERATIONS & STRATEGIC INITIATIVES
Luke Rajah, PhD
HEAD OF BUSINESS OPERATIONS & STRATEGIC INITIATIVES

Luke Rajah is Wren’s Head of Business Operations and Strategic Initiatives. Prior to Wren, Dr. Rajah worked as an Investment Director at Ombu Group, a Venture Capital company focused on the industrial and life sciences sectors, and as a Strategy Consultant with the Boston Consulting Group.Dr. Rajah graduated with bachelors and masters in Natural Sciences (Physics) and a PhD in Biophysical Chemistry from the University of Cambridge, where his research focused on the application of microfluidics and other biophysical techniques to protein misfolding.

Alleyn Plowright, PhD
HEAD OF DRUG DISCOVERY
Alleyn Plowright, PhD
HEAD OF DRUG DISCOVERY

Dr Plowright is Wren’s Head of Drug Discovery. He is a proven drug discovery leader with more than 20 years of experience across a range of therapeutic areas and has contributed to the delivery of a number of compounds to the clinic, including two compounds currently in Phase 2 clinical trials. Before joining Wren, Dr. Plowright was Head of Integrated Drug Discovery Germany for Sanofi, a multi-disciplinary research unit driving a broad drug discovery portfolio from target validation through preclinical development across a range of therapeutic modalities. Prior to Sanofi, Dr. Plowright spent 15 years with AstraZeneca in both the UK and Sweden, working with and leading cross-functional, multidisciplinary drug discovery teams as well as strategically driving scientific innovation. He is the author of more than 70 publications and patents. Dr. Plowright obtained his PhD in organic chemistry with Professor Gerald Pattenden at the University of Nottingham, UK in 1999 and continued with a two-year postdoctoral study in Chemical Biology with Professor Andrew Myers at Harvard University, U.S.

Kerry Jenkins, PhD
DIRECTOR, MEDICINAL CHEMISTRY
Kerry Jenkins, PhD
DIRECTOR, MEDICINAL CHEMISTRY
Andrew Cridland, PhD
MEDICINAL CHEMISTRY
Andrew Cridland, PhD
MEDICINAL CHEMISTRY
Bill Tatsis, PhD
COMPUTATIONAL CHEMISTRY
Bill Tatsis, PhD
COMPUTATIONAL CHEMISTRY
Suzanne Brewerton, PhD
HEAD OF DATA & ANALYTICS
Suzanne Brewerton, PhD
HEAD OF DATA & ANALYTICS

Dr. Brewerton is Wren’s Head of Data and Analytics. Previously, she worked at AstraZeneca where she was a senior leader in the R&D IT organisation, responsible for Data, Analytics and IT strategy for Oncology and Precision Medicine. Dr. Brewerton is a proven leader with more than 20 years’ experience working with teams in data engineering, data management, software engineering and analytics, including ML and AI, across various domains such as genomics, multi-omics and structure-based drug discovery. She has led multiple, matrixed, multi-disciplinary teams in both start-ups and pharma to build data and analytics platforms and has worked and lived in both the UK and Singapore. Dr. Brewerton completed her BSc in Biochemistry at the University of Manchester during which she became interested in computational biology and analytics. She then completed her PhD in protein structural bioinformatics at the University of Cambridge, where she studied the prediction of domain boundaries, repeating motifs and unstructured regions in proteins.

Johnny Habchi, PhD
VICE PRESIDENT, EARLY DISCOVERY
Johnny Habchi, PhD
VICE PRESIDENT, EARLY DISCOVERY

Dr. Habchi is a Founder and Vice President, Early Discovery for Wren. Previously, he worked at the Centre for Misfolding Diseases, Cambridge, where his research focused on developing new methodologies in drug discovery for protein aggregation. Dr. Habchi’s research included the first proof-of-principle studies demonstrating the mechanism of action of a small molecule drug targeting the misfolding and aggregation process, driven by a conceptual shift from structure-based to kinetics-based drug discovery in protein misfolding diseases. Dr. Habchi completed his BSc in Biochemistry at the Lebanese University during which he became interested in understanding the protein folding process. He then obtained masters and doctoral degrees in protein science from Aix-Marseille University, France, where he studied the folding of unstructured (intrinsically disordered) proteins. Dr. Habchi has co-authored more than 40 publications, is a Cambridge University Fellow in Leadership and a Fellow at Hughes Hall College, Cambridge.

Scott Pollack, PhD
VICE PRESIDENT, DISCOVERY ASSAY DESIGN AND INNOVATION
Scott Pollack, PhD
VICE PRESIDENT, DISCOVERY ASSAY DESIGN AND INNOVATION

Scott Pollack joined Wren Therapeutics in July 2022 as Vice President, Discovery Assay Design and Innovation. Prior to Wren, Dr. Pollack founded and led the biophysics group in the drug discovery CRO, Sygnature Discovery. He has extensive experience applying biophysics and enzymology to a broad range of drug discovery targets ranging from target validation and assay development through hit identification, characterization, and mechanistic analysis. Previous to his tenure with Sygnature, Dr. Pollack worked at Charles River and at the Merck Sharp and Dohme Neuroscience Research Centre, where he developed a strong pharmaceutical perspective applied to neurodegeneration targets and began exploring strategies for interfering with amyloidogenesis. Dr. Pollack has a BA in Chemistry from Harvard University and a PhD in Chemistry from the University of California, Berkeley, where his research focused on catalytic antibodies. He carried out postdoctoral research on mechanistic enzymology at Harvard.

Xiaoting Yang, PhD
PRINCIPAL SCIENTIST, PROTEIN BIOCHEMISTRY
Xiaoting Yang, PhD
PRINCIPAL SCIENTIST, PROTEIN BIOCHEMISTRY
Shimobi Onuoha, PhD
DIRECTOR, BIOLOGICS
Shimobi Onuoha, PhD
DIRECTOR, BIOLOGICS
Benedetta Mannini PhD
PRINCIPAL SCIENTIST, TRANSLATIONAL MODELS
Benedetta Mannini PhD
PRINCIPAL SCIENTIST, TRANSLATIONAL MODELS
Luke Rajah, PhD
HEAD OF BUSINESS OPERATIONS & STRATEGIC INITIATIVES
Luke Rajah, PhD
HEAD OF BUSINESS OPERATIONS & STRATEGIC INITIATIVES

Luke Rajah is Wren’s Head of Business Operations and Strategic Initiatives. Prior to Wren, Dr. Rajah worked as an Investment Director at Ombu Group, a Venture Capital company focused on the industrial and life sciences sectors, and as a Strategy Consultant with the Boston Consulting Group.Dr. Rajah graduated with bachelors and masters in Natural Sciences (Physics) and a PhD in Biophysical Chemistry from the University of Cambridge, where his research focused on the application of microfluidics and other biophysical techniques to protein misfolding.

Bochong Li, PhD
VICE PRESIDENT, INNOVATION
Bochong Li, PhD
VICE PRESIDENT, INNOVATION
Joe Wilson
FINANCE DIRECTOR
Joe Wilson
FINANCE DIRECTOR
Back to Top